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Aims To determine whether fibrin clot properties are associated with clinical outcomes following acute coronary syn-
drome (ACS).
...................................................................................................................................................................................................
Methods
and results
Plasma samples were collected at hospital discharge from 4354 ACS patients randomized to clopidogrel or ticagre-
lor in the PLATelet inhibition and patient Outcomes (PLATO) trial. A validated turbidimetric assay was employed
to study plasma clot lysis time and maximum turbidity (a measure of clot density). One-year rates of cardiovascular
(CV) death, spontaneous myocardial infarction (MI) and PLATO-defined major bleeding events were assessed after
sample collection. Hazard ratios (HRs) were estimated using Cox proportional hazards models. After adjusting for
CV risk factors, each 50% increase in lysis time was associated with CV death/spontaneous MI [HR 1.17, 95% confi-
dence interval (CI) 1.05–1.31; P< 0.01] and CV death alone (HR 1.36, 95% CI 1.17–1.59; P< 0.001). Similarly, each
50% increase in maximum turbidity was associated with increased risk of CV death (HR 1.24, 95% CI 1.03–1.50;
P= 0.024). After adjustment for other prognostic biomarkers (leukocyte count, high-sensitivity C-reactive protein,
high-sensitivity troponin T, cystatin C, N-terminal pro B-type natriuretic peptide, and growth differentiation factor-
15), the association with CV death remained significant for lysis time (HR 1.2, 95% CI 1.01–1.42; P= 0.042) but not
for maximum turbidity. These associations were consistent regardless of randomized antiplatelet treatment
(all interaction P> 0.05). Neither lysis time nor maximum turbidity was associated with major bleeding events.
...................................................................................................................................................................................................
Conclusion Fibrin clots that are resistant to lysis independently predict adverse outcome in ACS patients. Novel therapies tar-
geting fibrin clot properties might be a new avenue for improving prognosis in patients with ACS.
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Introduction
Adverse events, including cardiovascular (CV) death, remain com-
mon following acute coronary syndrome (ACS). Intensive antithrom-
botic therapies, including potent P2Y12 inhibitors and the addition of
low-dose anticoagulant therapy (rivaroxaban), have all resulted in
improved outcomes but increased the risk of major bleeding
events.1–3
There is marked overlap between risk factors for ischaemic and
bleeding events.4,5 Consequently, tailoring therapy to achieve the
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‘sweet spot’ of mitigating ischaemia whilst maintaining effective hae-
mostasis is an ongoing challenge and readily available biomarkers to
aid the decision process are lacking. Spontaneous major bleeding
events are associated with a similar prognosis to ischaemic events6
and, in patients undergoing percutaneous coronary intervention
(PCI), major bleeding events independently predict major CV
events.7
Following ACS, treatment includes aspirin and a P2Y12 inhibitor.
8,9
Although contemporary therapy effectively targets platelets,10,11
around 20% of patients suffer recurrent events within 12 months.5
This dual antiplatelet treatment strategy largely spares the protein
arm of coagulation, which leads to fibrin formation.
Patients with thrombotic conditions demonstrate unfavourable
fibrin clot structure.12–14 High-risk conditions, such as diabetes melli-
tus (DM), chronic kidney disease (CKD), and peripheral artery dis-
ease (PAD), have all shown associations with compact fibrin clots
and resistance to fibrinolysis.15–17 Factors contributing to this pheno-
type can include levels of clotting and lysis proteins, disease-specific
post-translational changes to fibrinogen, and genetic determi-
nants.18,19 Assessment of fibrin clot offers a functional evaluation of
the impact of all these factors on the protein arm of coagulation.
The majority of previous studies in this area used a cross-sectional
retrospective design and large-scale longitudinal studies are lacking.
We, therefore, aimed to study fibrin clot properties in plasma sam-
ples collected from ACS patients at hospital discharge and explore
the relationship between those characteristics and subsequent clini-
cal outcomes.
Methods
Study population and patient samples
The PLATelet inhibition and patient Outcomes (PLATO) trial was an
international multi-centre, double-blind, randomized controlled trial of
ticagrelor compared with clopidogrel in 18 624 moderate- to high-risk
ACS patients. The study design and results have previously been pub-
lished.1,20 Baseline patient characteristics, including medical and medica-
tion history, were recorded at baseline. Study visits were performed at 1,
3, 6, 9, and 12 months. In the PLATO biomarker sub-study,21 a subset of
4354 patients provided blood at hospital discharge, which was used for
this analysis in order to avoid the effects of anticoagulant therapy used as
part of the initial ACS management. Plasma was obtained from citrate-
anticoagulated venous blood samples and stored initially at –20C prior
to transfer to Uppsala Clinical Research Centre for storage at –80C. All
study patients provided written informed consent according to a proto-
col approved by local research ethics committees at participating centres.
For our analyses, frozen plasma samples were transferred to the
University of Sheffield and stored at –80C until analysis.
Fibrin clot assessment
Human thrombin was obtained from Merck Biosciences, recombinant tis-
sue plasminogen activator from Technoclone, calcium chloride dehydrate
and Tris from Fisher Scientific, and sodium chloride from Sigma Aldrich.
High-throughput turbidimetric analysis was performed in flat-bottomed,
polystyrene 96-well plates (Greiner) using a dedicated Multiskan FC
(Thermo Scientific) plate reader. Permeation buffer solution (100 mM
sodium chloride, 50 mM Tris, and pH 7.4) was used for dilution. Twenty
five lL aliquots of plasma (in duplicates) were mixed with 75lL lysis mix
and clots were formed by adding 50lL activation mix (tissue plasminogen
activator 83 ng/mL, calcium chloride 7.5 mM, and thrombin 0.03 U/mL;
final concentrations). After shaking for 2 s, plates were read at 340 nm
every 12 s at 37C until lysis in all samples was achieved. Quality control
samples were included in all plates. This method has previously been vali-
dated.12,22–24 Studied variables included lysis time (time taken for turbid-
ity to drop by 50% from maximum as a measure of lysis potential) and
maximum turbidity (turbidity refers to the scattering of light as a measure
of fibrin clot density). The co-efficient of variation was 8.3% for lysis time
and 3.8% for maximum turbidity. All analyses were performed blinded to
clinical outcome and clinical characteristics.
Other biochemical analyses
Plasma samples obtained at randomization were used to determine other
biomarker levels, as previously reported.21,25–27 Briefly, N-terminal pro
B-type natriuretic peptide (NT-proBNP), high-sensitivity troponin T, cys-
tatin C, C-reactive protein (CRP), and growth differentiation factor-15
(GDF-15) were measured using sandwich immunoassays. Differential
blood count was determined on EDTA-anticoagulated blood samples at
randomization.
Statistical methods
Biomarker levels were natural log-transformed before analysis. Baseline
patient characteristics, medical history, and biomarkers were compared
across quartile groups of each of the fibrin variables. Continuous data are
presented as medians and interquartile ranges and compared using
Kruskal–Wallis tests. Categorical data are presented as numbers and per-
centages and compared using v2 tests. The primary outcome of interest
was the composite of CV death and spontaneous myocardial infarction
(MI). Secondary outcomes were CV death alone, spontaneous MI alone,
stroke, all-cause mortality, definite or probable stent thrombosis accord-
ing to Academic Research Consortium criteria, PLATO-defined major
bleeding, and PLATO-defined bleeding unrelated to coronary artery
bypass graft surgery (CABG) (see Supplementary material online for
bleeding definitions). Kaplan–Meier curves were derived to compare
event rates across the four quartile groups of each of the fibrin clot varia-
bles. Cox-proportional hazards models were used to estimate hazard
ratios (HRs) and 95% confidence intervals (CIs). Hazard ratios are
expressed per 50% increase in fibrin variable level when assessed as con-
tinuous variables or compared to the lowest quartile of the fibrin variable
when assessed as categorical variables. Two models were used for adjust-
ment. Model 1 included randomized treatment, age, gender, body mass
index, smoking history, hypertension, dyslipidaemia, DM, CKD, ST-
elevation ACS and previous MI, congestive heart failure (CHF), revascu-
larisation, ischaemic stroke, or PAD.25–27 Model 2 included all variables in
Model 1 (excluding CKD) and the following inflammatory and prognostic
biomarkers: CRP, white blood cell count, cystatin C, NT-proBNP, tropo-
nin T, and GDF-15. The assumptions of proportional hazards were
assessed visually by calculating Schoenfeld residuals. To assess the prog-
nostic value of fibrin clot properties, Harrell’s C-index was estimated and
compared to a clinical predictive model (Model 1) without the addition
of fibrin clot variables using likelihood ratio tests. The efficacy and safety
of ticagrelor compared with clopidogrel according to fibrin clot proper-
ties was assessed using a Cox proportional hazards model that included
randomized treatment, continuous fibrin variable level using restricted
cubic splines, and randomized treatment by fibrin variable interaction.
The effect of fibrin clot properties on clinical outcome in relation to pre-
sentation was also assessed using a Cox proportional hazards model that
included presentation, continuous fibrin variable level using restricted
cubic splines, and presentation-by-fibrin-variable interaction. P-values
<0.05 from two-tailed tests were considered statistically significant. Due
to the exploratory nature of this study, P-values were not adjusted for
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..multiple testing. All statistical analyses were performed at Uppsala
Clinical Research Centre using R statistics software (Version 3.3.2; R
Foundation for Statistical Computing, Vienna, Austria).
Results
Relationships between fibrin clot
properties, clinical characteristics, and
biomarkers
A total of 4354 patients were included in this study. Table 1 and
Supplementary material online, Table S1 summarise the clinical char-
acteristics and biomarkers across the quartile groups of both lysis
time and maximum turbidity.
The prevalence of DM, hypertension, CKD, and female sex signifi-
cantly increased with increasing lysis time quartile group. Although
the differences were not significant, the highest quartile group of lysis
time appeared to have the highest prevalence of PAD and CHF.
Patients in the shortest lysis time quartile group tended to be older
but the absolute difference in mean age was small. Strong associations
were also observed between lysis time and other biomarkers: with
increasing quartile group, the levels of troponin T, NT-proBNP, CRP,
and white blood cell count increased. Growth differentiation factor-
15 and cystatin-C levels were also highest in the highest quartile
group.
Similar to lysis time, the prevalence of DM was highest in the high-
est quartile group of maximum turbidity. There was a higher percent-
age of female patients in the lowest maximum turbidity quartile
group. The relationship between maximum turbidity and the other
biomarkers was also pronounced (see Supplementary material
online, Table S1).
Neither lysis time nor maximum turbidity appeared to be affected
by haemoglobin or haematocrit.
Maximum turbidity and lysis time had a modest correlation
(Spearman correlation co-efficient 0.375, P< 0.001).
Fibrin clot properties and clinical
outcome
During follow-up, 125 (2.9%) patients had CV death, 183 (4.2%)
patients had spontaneous MI, and 41 (0.94%) patients had stroke.
There were 145 all-cause deaths (3.3%). Amongst those treated with
PCI (4335), 38 (0.88%) had definite or probable stent thrombosis.
.......................................................................................................................................
....................................................................................................................................................................................................................
Table 1 Baseline clinical characteristics and biomarkers across lysis time quartile groups
Variables Lysis time (s) quartile group P-value
Q1 (<564;
n51098)
Q2 (564–696;
n5 1108)
Q3 (696–888;
n5 1066)
Q4 (>888;
n5 1082)
Demographics and medical history
Age (years) 63 (55–72) 61 (54–70) 61 (53–70) 61 (53–70) <0.001
Female 242 (22.0) 318 (28.7) 271 (25.4) 442 (40.9) <0.001
Body mass index (kg/m2) 27.0 (24.5–29.7) 27.3 (24.9–30.1) 27.8 (25.3–30.8) 28.6 (25.6–31.8) <0.001
Current smoker 392 (35.7) 450 (40.6) 404 (37.9) 349 (32.3) <0.001
Hypertension 673 (61.3) 717 (64.7) 711 (66.7) 764 (70.6) <0.001
Hyperlipidaemia 453 (41.3) 462 (41.7) 456 (42.8) 469 (43.3) 0.744
Diabetes mellitus 206 (18.8) 221 (19.9) 242 (22.7) 305 (28.2) <0.001
Previous MI 216 (19.7) 215 (19.4) 214 (20.1) 201 (18.6) 0.843
Previous CHF 53 (4.8) 59 (5.3) 58 (5.4) 79 (7.3) 0.068
Previous stroke 34 (3.1) 42 (3.8) 35 (3.3) 40 (3.7) 0.783
PAD 62 (5.6) 68 (6.1) 63 (5.9) 80 (7.4) 0.345
CKD 29 (2.6) 42 (3.8) 27 (2.5) 49 (4.5) 0.028
Type of ACS
STE-ACS 504 (45.9) 522 (47.1) 510 (47.8) 486 (44.9) 0.536
Biomarkers
Troponin T (ng/L) 129 (35–453) 151 (37–511) 177 (46–582) 210 (47–755) <0.001
NT-proBNP (pmol/L) 387 (119–992) 386 (129–1088) 389 (131–1033) 469 (139–1433) 0.009
Cystatin C (mg/L) 0.80 (0.65–0.97) 0.80 (0.66–0.96) 0.81 (0.66–0.97) 0.86 (0.69–1.05) <0.001
GDF-15 (ng/L) 1503 (1095–2058) 1446 (1108–2092) 1509 (1182–2064) 1584 (1150–2254) 0.003
CRP (mg/L) 2.4 (1.1–5.8) 3.1 (1.4–7.6) 3.9 (1.8–9.8) 5.2 (2.2–13.5) <0.001
White cell count (109/L) 8.7 (6.9–10.9) 9.1 (7.3–11.4) 9.7 (7.8–11.9) 9.9 (7.8–12.5) <0.001
Haemoglobin (g/L) 141 (131–151) 142 (132–151) 142 (132–152) 141 (130–151) 0.144
Haematocrit (L/L) 0.41 (0.39–0.44) 0.42 (0.39–0.44) 0.42 (0.39–0.45) 0.42 (0.38–0.44) 0.265
Values are medians (IQRs) for continuous data and n (%) for categorical data. P-values calculated using v2 test (categorical variables) or Kruskal–Wallis test (continuous
variables).
CHF, congestive heart failure; CKD, chronic kidney disease; CRP, C-reactive protein; GDF, growth differentiation factor; MI, myocardial infarction; NT-proBNP, N-terminal pro
b-type natriuretic peptide; PAD, peripheral artery disease; STE-ACS, ST-elevation acute coronary syndrome.
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..PLATO-defined major bleeding occurred in 256 (5.9%) patients with
96 (2.2%) patients having non-CABG-related major bleeding.
Rates of the composite outcome of CV death and spontaneous MI
were higher in the highest quartile groups of both lysis time and maxi-
mum turbidity compared with rates in the lowest quartile groups
(Figure 1). This was primarily driven by higher rates of CV death in the
highest quartile groups (Figure 2). After adjustment for CV risk factors
(Model 1), the highest quartile group of lysis time was associated with
increased risk of CV death/spontaneous MI (HR 1.48, 95% CI 1.06–
2.06; P= 0.027) and CV death alone (HR 1.92, 95% CI 1.19–3.1;
P< 0.001). As a continuous variable, each 50% increase in lysis time
was associated with increased risk of CV death/spontaneous MI (HR
1.17, 95% CI 1.05–1.31; P= 0.006) and CV death alone (HR 1.36, 95%
CI 1.17–1.59; P< 0.001). This association remained significant for lysis
time after adjustment for inflammatory and prognostic biomarkers
(see Supplementary material online, Table S2). Similarly, each 50%
Figure 1 Relationship between fibrin clot parameters and 1-year cumulative event rate of cardiovascular death or spontaneous myocardial infarc-
tion. The Kaplan–Meier curves for cumulative event rate of the combined outcome of cardiovascular death or spontaneous myocardial infarction per
quartile group of lysis time (A) and maximum turbidity (B).
Figure 2 Relationship between fibrin clot parameters and 1-year cumulative event rate of cardiovascular death. The Kaplan–Meier curves for
1-year cumulative event rate of cardiovascular death per quartile group of lysis time (A) and maximum turbidity (B).
4 W. Sumaya et al.
Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehy013/4829678
by University of Sheffield user
on 06 February 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..increase in maximum turbidity was associated with CV death alone
(HR 1.24, 95% CI 1.03–1.50; P= 0.024) but this association was no
longer significant after adjustment for inflammatory and prognostic
biomarkers (see Supplementary material online, Table S3). Findings
for all-cause mortality were similar to those for CV death (see
Supplementary material online, Tables S2 and S3).
There was no clear association with rates of stent thrombosis and
stroke but event rates were low (data not shown). Neither lysis time
nor maximum turbidity was able to predict major bleeding events
(see Supplementary material online, Tables S2 and S3). Further char-
acterisation of bleeding events is provided in the Supplementary mate-
rial online, Tables S6 to S8.
There was no significant impact of fibrin clot properties on the CV
mortality reduction with ticagrelor compared with clopidogrel (inter-
action P> 0.7) (Figure 3). There was also no significant impact of fibrin
clot properties on the association between randomized treatment
and major bleeding (Figure 3). Similarly, the association between fibrin
clot properties and CV death was present irrespective of subtype of
ACS presentation (all interaction P> 0.05). A subset of patients
received low-molecular weight heparin on either the day of sampling
or the day before (see Supplementary material online, Tables S4 and
S5). This treatment did not affect the prognostic value of fibrin clot
parameters (all interaction P> 0.25).
Incremental prognostic value of lysis
time
Model performance to predict the composite outcome of CV death/
sMI significantly improved when lysis time was added to a clinical pre-
dictive model: C-index 0.67 (0.637–0.703) for Model 1þ lysis time
vs. 0.665 (0.631–0.698) for Model 1 only, P= 0.007. Prediction of CV
Figure 3 Relationship between fibrin clot parameters and 1-year rates of cardiovascular death or major bleeding according to randomized treat-
ment group. One-year rates of cardiovascular death (A and B) or major bleeding (C and D) in relation to maximum turbidity (A and C) or lysis time
(B and D), transformed using restricted cubic splines, according to randomized treatment with clopidogrel (C, pink lines) or ticagrelor (T, blue lines).
Shaded areas represent 95% confidence intervals. Vertical lines indicate quartiles.
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.death also significantly improved: C-index 0.7 (0.649–0.75) for Model
1þ lysis time vs. 0.69 (0.642–0.741) for Model 1 only, P< 0.001.
Discussion
We have shown, in a large population of ACS patients treated with
contemporary therapies and followed up for up to 1 year, that fibrin
clot properties independently predict the risk of spontaneous MI and
CV death following initial in-hospital management. Importantly, lysis
time predicted worse outcome after adjusting for other established
or new prognostic biomarkers, thus indicating the potential for a fur-
ther biomarker that provides insight into prognosis following ACS.
The association between lysis time and the levels of the established
biomarkers also raises the possibility that variability in fibrin clot
properties might contribute to the association of these other bio-
markers with thrombotic events (Take home figure). Given that antith-
rombotic therapy is mainly centred around antiplatelet agents
following the acute phase, our data support the hypothesis that at
least a subgroup of patients might benefit from additional therapy
that aims at improving lysis potential. For example, further work
could explore whether anticoagulant therapy, in combination with a
platelet P2Y12 receptor antagonist, offers an advantage over dual anti-
platelet therapy in those with adverse fibrin clot properties. Other
novel therapies that specifically target proteins implicated in impaired
lysis, such as complement C3 or plasmin inhibitor, is another
approach that might have less impact on haemostasis, particularly if
the aim was to normalise lysis potential.18
Studying fibrin clot properties is attractive for many reasons. First,
fibrinogen conversion and cross-linking of fibrin fibres to form a sta-
ble network is a key step in the formation of an obstructive vascular
thrombus. Second, thrombotic occlusion of coronary arteries could
represent a failure of the protective endogenous thrombolytic mech-
anisms to lyse clots before they become occlusive. Third, this assay
provides a functional and simple assessment of the complex interac-
tions between different clotting/lysis factors and other plasma pro-
teins and takes into account both quantitative and qualitative changes
in coagulation factors that may affect fibrinolytic efficiency.18,28
Fourth, this is a relatively cheap, easy and reproducible test to per-
form and, importantly, fibrin clots that resist lysis might give us mech-
anistic insights into recurrent events.
Previous studies, using different assays in whole blood, have shown
a positive association between prolonged lysis and CV death.29,30
Another study using thromboelastography in plasma showed similar
results.31 However, these were small studies with limited event rates
and assessment of clotting and lysis in whole blood cannot reliably dif-
ferentiate between the cellular and protein components of thrombus
formation.
The relationships between adverse fibrin clot dynamics and some
clinical characteristics demonstrated in our work are consistent with
evidence obtained from smaller observational, cross-sectional
Take home Figure High-risk conditions are associated with increased thrombotic potential through a variety of mechanisms. Dual antiplatelet
therapy successfully targets platelet reactivity. However, hypofibrinolysis remains unaffected and constitutes a potential therapeutic target. LDL-C,
low-density lipoprotein cholesterol; PAI-1, plasminogen activation inhibitor-1; TAFI, thrombin activatable fibrinolysis inhibitor.
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studies. For example, DM, CKD, and PAD, all high-risk conditions for
cardiac ischaemia, have shown associations with adverse fibrin clot
characteristics.15–17
Available biomarkers have added little incremental prognostic value
beyond a clinical predictive model and therefore their clinical use has
been limited in secondary prevention of CV disease.32 Although the
added prognostic value of lysis time is also modest, identifying patients
with adverse fibrin clot properties might help direct therapy beyond
the current approach of antiplatelet therapy in these patients.
Evidence suggests that inflammation results in prothrombotic
states.33,34 The strong correlations between fibrin clot properties and
inflammatory markers support previous work demonstrating that
inflammation leads to prothrombotic changes in fibrin clot dynamics
and illustrates one mechanism for the higher risk of atherothrombotic
events in patients with higher levels of inflammatory markers.35,36
The relationship between maximum turbidity and worse out-
comes lost significance after adjusting for other biomarkers.
Fibrinogen levels have a greater effect on maximum turbidity com-
pared with lysis time24,37 (see also Supplementary material online,
Figure S5) and fibrinogen levels go hand-in-hand with inflammatory
markers, particularly CRP.38
Interestingly, fibrin clot density and resistance to lysis increased
with increasing levels of NT-proBNP and troponin T. The exact
molecular mechanism for this association is difficult to ascertain.
However, higher troponin T and NT-proBNP reflect larger infarcts
and these are associated with a greater inflammatory response, which
might account for some of the prothrombotic changes. NT-proBNP
has been shown to add prognostic value regardless of the degree of
necrosis after ACS.39 Our findings, therefore, point to an additional
mechanism, beyond the increased risks of death from heart failure
and arrhythmia associated with left ventricular systolic dysfunction,
whereby NT-proBNP is associated with worse outcome, as a conse-
quence of more dense fibrin clots that resist lysis leading to increased
risk of atherothrombosis.
Turbidimetric analysis of fibrin clots requires trained laboratory per-
sonnel, and therefore, is not suitable as a bedside test. Similar to other
clotting assays, results might be influenced by high-level anticoagulant
therapy and significant liver conditions, which make results difficult to
interpret in those scenarios. A limitation to this study is that it only pro-
vides a ‘snapshot’ assessment of fibrin clot characteristics at hospital
discharge (median 6 days). It is established that internal fibrinolytic
activity has a circadian rhythm largely driven by variations in plasmino-
gen activator inhibitor—1 activity.40 Unfortunately sampling times are
not available in our database but samples were collected during office
working hours. The clear relationship with DM and biomarker levels,
which were all measured at baseline, reassure us that the influence of
circadian variation is likely to be marginal. Future analyses will seek to
assess the stability of this phenotype over time and how the relation-
ship with clinical outcome could change in a stable patient cohort.
Conclusions
Despite strong relationships with clinical risk factors, particularly DM,
and inflammatory and other prognostic biomarkers, the resistance of
fibrin clots to lysis independently predicts CV death following ACS.
These findings suggest that novel therapies targeting fibrin clot
properties might be a new avenue for improving clinical outcomes in
patients with ACS.
Supplementary material
Supplementary material is available at European Heart Journal online.
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